Shanton Pharma is a clinical-stage biotech company founded in 2016, with a research focus on the unmet needs associated with gout, hyperuricemia, and pruritus. Our team focuses its resources on these important therapeutic areas through advanced and innovative drug research and developmental approaches.
At Shanton Pharma our mission is to address the global clinical unmet needs associated with gout, hyperuricemia, and pruritus. Our ultimate goal for gout is to completely eliminate the disease.
We strive to bring innovative new medicines to patients and the medical communities we serve, by focusing on the development and commercialization of our core products.
Shanton Pharma is dedicated to researching and developing novel and innovative solutions for gout, hyperuricemia, and pruritus.
Read More
SAP-001 is Shanton’s lead investigational compound with Best-in-Class potential in uncontrolled gout
The Shanton Pharma Phase 2 study evaluating its investigational product SAP-001, an oral, small molecule, achieved its primary endpoint. In the trial,...
– Established China Biotechnology Company with Global Headquarters in the United States – Proceeds will advance clinical development of SAP-001 clini...
